skip to Main Content

Veredus VereCoV™ Detection Kit

Category

Test kits

Subcategory

PCR test

Manufacturer

Veredus

Company origin

Singapore

Certifications & Standards

HSA (Singapore)

Brief description

VereCoV™ Detection Kit is a multiplex RT-PCR and microarray-based test. This test is for use in conjunction with the VerePLEX™ Biosystem. The test is intended for qualitative detection, differentiation and identification of 2019 Novel Coronavirus (2019-nCoV) Severe Acute Respiratory Syndrome-related Coronavirus (SARS-CoV).

Lab COVID-19 Trust Score

Trust score: 85%
Reviewer comment: HSA (Singapore) approved but no CE or FDA approval.

Photos

Detailed information

Overview

VereCoV™ Detection Kit is a multiplex RT-PCR and microarray-based test. This test is for use in conjunction with the VerePLEX™ Biosystem. The test is intended for qualitative detection, differentiation and identification of the following viral RNA in a single test.

  • 2019 Novel Coronavirus (2019-nCoV)
  • Severe Acute Respiratory Syndrome-related Coronavirus (SARS-CoV)

VereCoV™ Detection Kit and VerePLEX™ Biosystem are issued with Provisional Authorisation from the Heath Sciences Authority (Singapore) as medical devices to supply in Singapore intended for In-vitro Diagnostic (IVD) use.

Milestones

  • Approved by HSA (Singapore) for research use only.

Features

  • Multiplex amplification reactions
  • Multiple probes per target ensures reliable detection
  • Small sample volume requirement
  • Fast and programmable temperature ramp rate
  • Scalable for high throughput
  • PCR yield is comparable to standard thermal cyclers
  • Functional validation of hybridization for each assay is provided by an internal positive hybridization control
  • Proprietary microfluidic interface: contact surfaces are biocompatible and do not inhibit the PCR reaction
  • Short-time required for fluidic operations

Advantages

Speed; viral RNA samples to results in less than 2.5 hours.

Specificity; detection of specific targets for 2019-nCoV and SARS-CoV without cross-reactivity with other coronaviruses such as OC43, 229E, KhU1, NL63.

Comprehensive; qualitatively detect 2019-nCoV with the additional capability of detecting a subset of SARS-CoV simultaneously within the same test.

Mobile; the VerePLEX™ Biosystem is designed to be portable for usage at areas such as checkpoints and borders.

Easy to Use; the simple workflow allows for minimally trained or non-scientific personnel to run tests.

Updates Available; probes can be updated quickly to include new mutations of the evolving coronaviruses and ensure the right coverage of detection.

Biosystem technology

The VerePLEX™ Biosystem combines molecular biology, microfluidics and microelectronics to bring the future of diagnostics and surveillance to you today. The VerePLEX™ Biosystem, along with the VereChip™, is a breakthrough in innovation, integrating two powerful molecular biological technologies: PCR and Microarray. VerePLEX™ Biosystem includes the following components:

  • Temperature Control System (5 random access modules)
  • Optical Reader
  • Biosystem Software
  • Barcode Reader

Media coverage